These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1428461)

  • 1. New approaches to assess topical corticosteroid bioequivalence: pharmacokinetic evaluation.
    Pershing LK
    Int J Dermatol; 1992 Oct; 31 Suppl 1():14-20. PubMed ID: 1428461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical 0.050% betamethasone dipropionate. Pharmacokinetic and pharmacodynamic dose-response studies in humans.
    Pershing LK; Lambert L; Wright ED; Shah VP; Williams RL
    Arch Dermatol; 1994 Jun; 130(6):740-7. PubMed ID: 8002644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian activity of topical 0.05% betamethasone dipropionate in human skin in vivo.
    Pershing LK; Corlett JL; Lambert LD; Poncelet CE
    J Invest Dermatol; 1994 May; 102(5):734-9. PubMed ID: 8176255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability.
    Wiedersberg S; Naik A; Leopold CS; Guy RH
    Br J Dermatol; 2009 Mar; 160(3):676-86. PubMed ID: 18782322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay.
    Pershing LK; Silver BS; Krueger GG; Shah VP; Skelley JP
    Pharm Res; 1992 Jan; 9(1):45-51. PubMed ID: 1589409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data.
    Schwarb FP; Smith EW; Haigh JM; Surber C
    Eur J Pharm Biopharm; 1999 May; 47(3):261-7. PubMed ID: 10382110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical corticosteroids: quality control considerations.
    Shah VP
    Int J Dermatol; 1992 Oct; 31 Suppl 1():34-7. PubMed ID: 1428466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing.
    Demana PH; Smith EW; Walker RB; Haigh JM; Kanfer I
    Pharm Res; 1997 Mar; 14(3):303-8. PubMed ID: 9098871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence Methodologies for Topical Drug Products: In Vitro and Ex Vivo Studies with a Corticosteroid and an Anti-Fungal Drug.
    Leal LB; Cordery SF; Delgado-Charro MB; Bunge AL; Guy RH
    Pharm Res; 2017 Apr; 34(4):730-737. PubMed ID: 28097506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vasoconstrictor assay in bioequivalence testing: practical concerns and recent developments.
    Stoughton RB
    Int J Dermatol; 1992 Oct; 31 Suppl 1():26-8. PubMed ID: 1428464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blanching activities of betamethasone formulations. The effect of dosage form on topical drug availability.
    Smith EW; Meyer E; Haigh JM
    Arzneimittelforschung; 1990 May; 40(5):618-21. PubMed ID: 2383308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence assessment of topical clobetasol propionate products using visual and chromametric assessment of skin blanching.
    Au WL; Skinner M; Kanfer I
    J Pharm Pharm Sci; 2008; 11(1):160-6. PubMed ID: 18445371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
    Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
    Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of skin stripping, in vitro release, and skin blanching response methods to measure dose response and similarity of triamcinolone acetonide cream strengths from two manufactured sources.
    Pershing LK; Bakhtian S; Poncelet CE; Corlett JL; Shah VP
    J Pharm Sci; 2002 May; 91(5):1312-23. PubMed ID: 11977107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel foam vehicle for delivery of topical corticosteroids.
    Huang X; Tanojo H; Lenn J; Deng CH; Krochmal L
    J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S26-38. PubMed ID: 15968261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of dermal bioavailability: predicting the input function for topical glucocorticoids using stratum corneum sampling.
    Pensado A; McGrogan A; White KAJ; Bunge AL; Guy RH; Delgado-Charro MB
    Drug Deliv Transl Res; 2022 Apr; 12(4):851-861. PubMed ID: 34599470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of the vasoconstrictive activity of preparations containing topical corticosteroids].
    Henschel V; Jaminet F
    J Pharm Belg; 1974; 29(1):3-15. PubMed ID: 4831715
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro penetration through the skin layers of topically applied glucocorticoids.
    Carrer V; Alonso C; Oliver MA; Coderch L
    Drug Test Anal; 2018 Oct; 10(10):1528-1535. PubMed ID: 29788546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of chromameter results obtained from corticosteroid-induced skin blanching. I: Manipulation of data.
    Smith EW; Haigh JM; Walker RB
    Pharm Res; 1998 Feb; 15(2):280-5. PubMed ID: 9523316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of topical drugs within the skin, in particular glucocorticoids.
    Kubota K; Ademola J; Maibach HI
    Curr Probl Dermatol; 1993; 21():61-6. PubMed ID: 8299377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.